Crucell (CRXL) Announces Positive Results of Phase II Rabies Monoclonal Antibody Combination Clinical Study in Philippines
Dutch biopharmaceutical company Crucell N.V. (Nasdaq: CRXL) announced the results of a second phase II clinical study of its investigational rabies monoclonal antibody combination, which started in May 2008 in the Philippines.
Crucell has a collaboration and commercialization agreement with sanofi pasteur, the vaccines division of sanofi-aventis Group, for Crucell's rabies monoclonal antibodies to be used in association with a rabies vaccine for post-exposure prophylaxis against the fatal disease of rabies.
Related Categories
Corporate NewsFDA
Stocks Mentioned
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
